Amgen Inc (AMGN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Amgen Inc   (NASDAQ: AMGN)


Amgen Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Amgen Inc's ROI in the second quarter of 2026?
Amgen Inc achieved a return on average invested assets (ROI) of 13.36 % in its second quarter of 2026, this is above AMGN's average return on investment of 10.94%.
Amgen Inc s investments during the 12 months ending in the second quarter of 2026 are valued at $65 billion

ROI has improved compared to 12.3% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 73 other companies had a higher return on investment. While the total ranking for ROI remained the same, compared to the first quarter of 2026 at no. 658.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 1.53 % -2.22 % -5.03 % -7 % -7.82 %
Y / Y Net Income Change TTM 32.09 % 31.47 % 83.46 % 95.89 % 787.27 %
Investment (TTM) in Millions 71,860 63,840 61,353 64,669 63,699
Return On Investment (TTM) 13.36 % 12.3 % 12.22 % 10.95 % 10.27 %
AMGN's Overall Ranking # 658 # 658 # 558 # 290 # 602
Seq. Investment Change TTM 3.22 % 0.48 % -1.34 % -0.77 % -0.6 %
Seq. Net Income Change TTM 12.09 % 1.15 % 10.08 % 5.83 % 11.56 %
Net Income (TTM) in Millions 8,743 7,800 7,711 7,005 6,619

AMGN Company Profile >> Back to AMGN Roi Comparisons >> See Annual AMGN Return On Investment



Return On Investment AMGN's Ranking
Within: No.
Industry # 14
Sector # 74
Overall # 658

Return On Investment Statistics
High Average Low
19.24 %
10.94 %
2.81 %
(Dec 31 2019)   (Dec 31 2017)







Financial Statements
Amgen Inc's II. Quarter Investments $ 71,860 Millions AMGN's Balance sheet
Amgen Inc's II. Quarter Income $ 2,375 Millions Quarterly AMGN's Income Statement
AMGN's Income by Division See AMGN's Income by Division


AMGN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 61,353 64,775 74,082 46,772 48,981
Y / Y Investment Growth -5.28 % -12.56 % 58.39 % -4.51 % -4.51 %
Net Income in Millions 7,711 4,090 6,717 6,552 5,893
Y / Y Net Income Growth 88.53 % -39.11 % 2.52 % 11.18 % -18.87 %
Annual Return On Investment 12.57 % 6.31 % 9.07 % 14.01 % 12.03 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 12.57 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AMGN's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AMGN's Competitors
Subscribers only: Roi for Amgen Inc's Suppliers
Subscribers only: Return On Investment for AMGN's Customers

Other Ratios
AMGN's Roa AMGN's Inventory Turnover Ratio AMGN's Growth Rates AMGN's Dividend Statistics
AMGN's Profitability Ratios AMGN's Asset Turnover Ratio AMGN's Dividend Growth
AMGN's Roe AMGN's Valuation Ratios AMGN's Financial Strength Ratios AMGN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %

Date modified: 2026-09-13T23:23:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.